IL1B and pericarditis: In recent years, IL-1 inhibitors have revolutionized therapy for recurrent pericarditis refractory to conventional treatment.6–9 However, a subset of patients cannot tolerate IL-1 agents (as in our case) or may show persistent disease despite IL-1 blockade.